Genetic Variants of Tumor Necrosis Factor Superfamily, Member 4 (TNFSF4), and Risk of Incident Atherothrombosis and Venous Thromboembolism (Molecular Diagnostics and Genetics) Genetic Variants of Tumor Necrosis Factor Superfamily, Member 4 (TNFSF4), and Risk of Incident Atherothrombosis and Venous Thromboembolism (Molecular Diagnostics and Genetics)

Genetic Variants of Tumor Necrosis Factor Superfamily, Member 4 (TNFSF4), and Risk of Incident Atherothrombosis and Venous Thromboembolism (Molecular Diagnostics and Genetics‪)‬

Clinical Chemistry 2008, May, 54, 5

    • 29,00 kr
    • 29,00 kr

Utgivarens beskrivning

Vascular inflammation is a key component in the development and progression of cardiovascular disease (CVD)3 and venous thromboembolism (VTE). Understanding of the processes that initiate and maintain inflammation has increased with the characterization of new disease pathways in the adaptive and innate immune systems. One such pathway is the receptor-ligand pair Ox40-Ox40 ligand (Ox40L), which has shown association with atherosclerosis in both mouse and human (1). Interruption of the Ox40-Ox40L pathway attenuates atherogenesis in LDL receptor --deficient mice (2). Ox40L is a 34-kDa glycoprotein belonging to the tumor necrosis superfamily. The expression of Ox40L has been observed in T cells, B lymphocytes, vascular endothelial cells, and importantly, dendritic cells (3-5). Cross-linking of Ox40L with Ox40 provides a T-cell costimulatory signal, resulting in increased proliferation and cytokine production (4, 5). In addition, there is evidence that Ox40L inhibits interleukin (IL)-10 production and suppresses the function of IL-10-producing T cells, which may be a unique function of Ox40L to regulate immunity and tolerance (2). Attributable to the immunoregulatory role of this pathway, interactions between Ox40 and Ox40L have the potential to enhance inflammatory responses in atherosclerotic plaque.

GENRE
Vetenskap och natur
UTGIVEN
2008
1 maj
SPRÅK
EN
Engelska
LÄNGD
20
Sidor
UTGIVARE
American Association for Clinical Chemistry, Inc.
STORLEK
236,9
KB

Fler böcker av Clinical Chemistry

D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report) D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report)
2004
Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs) Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs)
2005
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs) Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs)
2005
Newborn Screening for Lysosomal Storage Disorders (Editorials) Newborn Screening for Lysosomal Storage Disorders (Editorials)
2005
Inadequate Attempts to Measure the Microheterogeneity of Transthyretin by Low-Resolution Mass Spectrometry (Letters) (Letter to the Editor) Inadequate Attempts to Measure the Microheterogeneity of Transthyretin by Low-Resolution Mass Spectrometry (Letters) (Letter to the Editor)
2005